Clinical trial · Interventional
Central-boost Ablative Radiation Therapy for Solid Tumors (CBART)
Central-boost Ablative Radiation Therapy for Large Tumors or Tumors Adjacent to Organs at Risk
NCT06427460CI-TRIAL-00077398recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In the case of large tumors or tumors closely adjacent to organs at risk, ablative doses offered by stereotactic body radiation therapy (SBRT) could not be delivered. Therefore, a technique that could provide high radiation doses to tumors without increasing of risks of severe adverse effects is required.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Central-boost ablative dose delivered by stereotactic body radiation therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- stereotactic body radiation therapy
- description
- Central-boost ablative doses delivered by SBRT.
- interventionNames
- Radiation: Central-boost ablative dose delivered by stereotactic body radiation therapy
Primary outcomes (1)
- measure
- One-year local control will be determined.
- timeFrame
- 1 year
- description
- The proportion of patients without tumor local progression at one year. The progression is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Secondary outcomes (3)
- measure
- Overall survival will be determined.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 18-75 years. * Pathologically confirmed lung, liver, pancreas or retroperitoneal malignant tumor. * Oligometastasis in the case of metastatic tumor * the shortest diameter ≥2cm or the distance from the tumor to the organs at risk less than 5mm * ECOG of 0 to 1 point * No abnormality in blood routine test, liver and kidney function test and coagulation test (White blood cell count ≥4.0×10\^9/L, neutrophil count ≥2.0×10\^9, hemoglobin level ≥100g/L, platelet count ≥100×10\^9/L, ALT and AST level \< 2.5 times the upper limit of normal, total bilirubin and creatinine level within the normal, international normalized ratio \<2) Exclusion Criteria: * History of radiotherapy for the lesion * History of tumor within 5 years * ECOG ≥2 points * Significant abnormality in blood routine test, liver and kidney function test and coagulation test * Active inflammatory bowel disease in the case of pancreas or retroperitoneal tumor * Gastrointestinal bleeding or perforation within 6 months in the case of pancreas or retroperitoneal tumor * Infections required antibiotics * Heart or respiratory insufficiency * Pregnant or breastfeeding women
References
Publications (0)
Data not yet available
No reference posted for this study.